Literature DB >> 20668106

Chronic kidney injury in patients after cardiac catheterisation or percutaneous coronary intervention: a comparison of radial and femoral approaches (from the British Columbia Cardiac and Renal Registries).

Tycho Vuurmans1, Jonathan Byrne, Eric Fretz, Christian Janssen, J David Hilton, W Peter Klinke, Ognjenka Djurdjev, Adeera Levin.   

Abstract

BACKGROUND: Acute kidney injury (AKI) is a well-recognised complication of cardiac catheterisation and percutaneous coronary intervention (PCI). However, the incidence of chronic kidney disease (CKD) after catheterisation and PCI has not been fully evaluated. A number of risk factors have been implicated in the development of AKI following cardiac catheterisation. Transradial access could lead to a lower incidence of CKD after catheterisation or PCI because of less catheter contact with aortic atheroma, and reduced potential for atheroembolism.
OBJECTIVE: To determine the incidence of CKD onset and its association with arterial access in patients after cardiac catheterisation or PCI. METHODS AND
RESULTS: Linkages between the British Columbia (BC) Cardiac Registry (N=69 214) patients who underwent catheterisation or PCI between 1999 and 2005 and the BC Renal Database were determined. Within 6 months after the cardiac procedure 0.4% of patients developed dialysis dependency, 0.2% in the transradial versus 0.4% in the transfemoral group (p<0.0001); 0.3% of patients developed stage 4 or 5 CKD, 0.1% in the transradial versus 0.4% in the transfemoral group (p<0.0001); 0.9% of patients developed new CKD, 0.2% in the transradial versus 1.2% in the transfemoral group (p<0.0001). After adjusting for baseline characteristics the femoral access site had an OR of 4.36 (95% CI 2.48 to 7.66) for the development of the composite end point of new dialysis, new stage 4 or 5 CKD or new CKD.
CONCLUSIONS: In this large database of current practice coronary catheterisation and PCI, the incidence of CKD onset within 6 months of the procedure was 0.9%. The transradial access site is associated with less CKD than the femoral approach.

Entities:  

Mesh:

Year:  2010        PMID: 20668106     DOI: 10.1136/hrt.2009.192294

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  23 in total

1.  Interventional cardiology: Hand me your radial artery to protect your kidney.

Authors:  Giora Weisz; Martin B Leon
Journal:  Nat Rev Cardiol       Date:  2010-12       Impact factor: 32.419

2.  Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable?

Authors:  Neil J Wimmer; David J Cohen; Jason H Wasfy; Saif S Rathore; Laura Mauri; Robert W Yeh
Journal:  Am Heart J       Date:  2014-04-04       Impact factor: 4.749

Review 3.  Contrast medium induced acute kidney injury: a narrative review.

Authors:  Valentina Pistolesi; Giuseppe Regolisti; Santo Morabito; Ilaria Gandolfini; Silvia Corrado; Giovanni Piotti; Enrico Fiaccadori
Journal:  J Nephrol       Date:  2018-05-25       Impact factor: 3.902

4.  Guideline on the use of iodinated contrast media in patients with kidney disease 2018.

Authors:  Yoshitaka Isaka; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Yoshio Terada; Kent Doi; Yoshihide Fujigaki; Hideo Yasuda; Taichi Sato; Tomoyuki Fujikura; Ryohei Kuwatsuru; Hiroshi Toei; Ryusuke Murakami; Yoshihiko Saito; Atsushi Hirayama; Toyoaki Murohara; Akira Sato; Hideki Ishii; Tadateru Takayama; Makoto Watanabe; Kazuo Awai; Seitaro Oda; Takamichi Murakami; Yukinobu Yagyu; Nobuhiko Joki; Yasuhiro Komatsu; Takamasa Miyauchi; Yugo Ito; Ryo Miyazawa; Yoshihiko Kanno; Tomonari Ogawa; Hiroki Hayashi; Eri Koshi; Tomoki Kosugi; Yoshinari Yasuda
Journal:  Clin Exp Nephrol       Date:  2020-01       Impact factor: 2.801

Review 5.  Prevention of Contrast and Radiation Injury During Coronary Angiography and Percutaneous Coronary Intervention.

Authors:  Arash Ehteshami Afshar; Puja B Parikh
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-22

6.  Guideline on the use of iodinated contrast media in patients with kidney disease 2018.

Authors:  Yoshitaka Isaka; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Yoshio Terada; Kent Doi; Yoshihide Fujigaki; Hideo Yasuda; Taichi Sato; Tomoyuki Fujikura; Ryohei Kuwatsuru; Hiroshi Toei; Ryusuke Murakami; Yoshihiko Saito; Atsushi Hirayama; Toyoaki Murohara; Akira Sato; Hideki Ishii; Tadateru Takayama; Makoto Watanabe; Kazuo Awai; Seitaro Oda; Takamichi Murakami; Yukinobu Yagyu; Nobuhiko Joki; Yasuhiro Komatsu; Takamasa Miyauchi; Yugo Ito; Ryo Miyazawa; Yoshihiko Kanno; Tomonari Ogawa; Hiroki Hayashi; Eri Koshi; Tomoki Kosugi; Yoshinari Yasuda
Journal:  Jpn J Radiol       Date:  2020-01       Impact factor: 2.374

7.  Advantages of a workbench reshaped AR1 mod catheter for right coronary angiography by right radial approach.

Authors:  Cesare Baldi; Marco Mirra; Marco Di Maio; Tiziana Attisano; Michele Roberto Di Muro; Francesco Vigorito; Rosario Farina; Maria Vincenza Polito; Pietro Giudice; Federico Piscione
Journal:  Interv Med Appl Sci       Date:  2014-03-14

Review 8.  Acute kidney injury among ST elevation myocardial infarction patients treated by primary percutaneous coronary intervention: a multifactorial entity.

Authors:  Yacov Shacham; Arie Steinvil; Yaron Arbel
Journal:  J Nephrol       Date:  2016-02-10       Impact factor: 3.902

9.  Radial access protects from contrast media induced nephropathy after cardiac catheterization procedures.

Authors:  Thorsten Feldkamp; Maya Luedemann; Martina E Spehlmann; Sandra Freitag-Wolf; Julia Gaensbacher; Kevin Schulte; Amer Bajrovic; Dieter Hinzmann; Hans-Joerg Hippe; Ulrich Kunzendorf; Norbert Frey; Mark Luedde
Journal:  Clin Res Cardiol       Date:  2017-09-22       Impact factor: 5.460

10.  Letter to the Editor re: Are intravenous injections of contrast media really less nephrotoxic than intra-arterial injections?

Authors:  Piero Stratta; Cristina Izzo; Caterina Canavese; Marco Quaglia
Journal:  Eur Radiol       Date:  2013-02-01       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.